FDA panel expresses concern about tamper-resistant OxyContin

05/5/2008 | Google · Wall Street Journal, The

FDA advisers have called for more tests to confirm the purportedly abuse-resistant features of a new formulation of OxyContin, Purdue Pharma LP's pain drug. Most of the panel members said that including data about the drug's tamper-resistant qualities on the label may lead to more overdoses and deaths. An official with the company, however, said studies found the new version of the drug "substantially more difficult" to alter because it cannot be easily dissolved or pulverized.

View Full Article in:

Google · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC